Valemetostat Tosylate
Valemetostat Tosylate is a pharmaceutical drug with 7 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
6
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Clinical Trials (7)
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7